Fusion’s $2B Acquisition: Exciting AstraZeneca Deal Brings $24/Share Windfall
Fusion Pharmaceuticals (NASDAQ:FUSN) will be acquired by AstraZeneca (NASDAQ:AZN) for $21/share upfront and $3/share later, with a $2B merger closing in Q2.
Anglo American’s Bold Move: $7.9B Coal Asset Sale Sparks High Interest
Anglo American has initiated a formal process to sell its coal assets and explore options for its nickel operations to thwart BHP's takeover threat and stay independent, according to CEO Duncan Wanblad.
Game-Changing $2B Deal: AstraZeneca’s Bold Acquisition of Fusion Pharmaceuticals Gets Overwhelming Approval
Fusion Pharmaceuticals shareholders have overwhelmingly approved its ~$2B acquisition by AstraZeneca, expected to close by the end of Q2.
Breaking: BHP Urges Deadline Extension Amid Stalled Talks with Anglo American – Will the 11th-Hour Proposal Seal the Deal?
"BHP (NYSE:BHP) seeks an extension for talks with Anglo American (OTCQX:AAUKF) on its takeover proposal, citing proposed socioeconomic measures and the need for further engagement, with the deadline for merger talks looming."